NASDAQ:ELDN Eledon Pharmaceuticals (ELDN) Stock Price, News & Analysis $2.67 -0.09 (-3.26%) Closing price 11/11/2026 04:00 PM EasternExtended Trading$2.68 +0.00 (+0.19%) As of 11/11/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Eledon Pharmaceuticals Stock (NASDAQ:ELDN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Eledon Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.64▼$2.8250-Day Range$2.13▼$3.0452-Week Range$1.35▼$4.49Volume530,432 shsAverage Volume919,959 shsMarket Capitalization$216.97 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingHold Company Overview Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that selectively modulate the immune system for patients with life-threatening diseases. The company’s research is centered on conditions involving immune activation, including organ transplantation, autoimmune disorders and other inflammatory diseases. Eledon’s lead product candidate is tegoprubart, a monoclonal antibody designed to block CD40 ligand, a protein involved in immune-system signaling. The company has evaluated tegoprubart in clinical programs involving kidney transplantation, islet-cell transplantation and amyotrophic lateral sclerosis, and continues to investigate its potential in transplantation and other immune-mediated conditions. The company was formerly known as Novus Therapeutics, Inc. and adopted the name Eledon Pharmaceuticals, Inc. in 2020. Eledon is headquartered in Irvine, California, and does not currently have a marketed commercial product; its activities primarily involve research, clinical development and collaboration with medical and scientific institutions.AI Generated. May Contain Errors. Read More Eledon Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreELDN MarketRank™: 1.962133123685 of 5 starsEledon Pharmaceuticals scored higher than 39% of companies evaluated by MarketBeat, and ranked 688th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingEledon Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialEledon Pharmaceuticals has a consensus price target of $10.00, representing about 274.5% upside from its current price of $2.67.Amount of Analyst CoverageEledon Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Eledon Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Eledon Pharmaceuticals is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eledon Pharmaceuticals is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEledon Pharmaceuticals has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Eledon Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.24% of the float of Eledon Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEledon Pharmaceuticals has a short interest ratio ("days to cover") of 7.51.Change versus previous monthShort interest in Eledon Pharmaceuticals has recently increased by 4.51%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEledon Pharmaceuticals does not currently pay a dividend.Dividend GrowthEledon Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.91 News SentimentEledon Pharmaceuticals has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Eledon Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest5 people have searched for ELDN on MarketBeat in the last 30 days. MarketBeat Follows4 people have added Eledon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Eledon Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders9.60% of the stock of Eledon Pharmaceuticals is held by insiders.Percentage Held by Institutions56.77% of the stock of Eledon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Eledon Pharmaceuticals' insider trading history. Receive ELDN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eledon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ELDN Stock News HeadlinesEledon Pharmaceuticals (ELDN) Set to Release Quarterly Earnings on FridayNovember 6, 2026 | americanbankingnews.comEledon Pharmaceuticals, Inc. Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements In Quality Of Life And Symptom Burden With Tegoprubart Compared To Tacrolimus At ...October 26, 2026 | marketscreener.comMURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it. | Paradigm Press (Ad)Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at ...October 26, 2026 | markets.businessinsider.comEledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual MeetingOctober 26, 2026 | globenewswire.comEledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual MeetingOctober 5, 2026 | globenewswire.comEledon Pharmaceuticals, Inc. (ELDN)September 25, 2026 | finance.yahoo.comEledon Pharmaceuticals, Inc. Presents Updated Long-Term Phase 2 BESTOW Extension Study Results For Tegoprubart And Announces FDA Fast Track DesignationSeptember 23, 2026 | marketscreener.comMSee More Headlines ELDN Stock Analysis - Frequently Asked Questions How have ELDN shares performed this year? Eledon Pharmaceuticals' stock was trading at $1.51 at the beginning of the year. Since then, ELDN shares have increased by 76.8% and is now trading at $2.67. How were Eledon Pharmaceuticals' earnings last quarter? Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) issued its quarterly earnings results on Thursday, August, 13th. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.11. When did Eledon Pharmaceuticals IPO? Eledon Pharmaceuticals (ELDN) raised $91 million in an initial public offering on Wednesday, September 17th 2014. The company issued 6,480,000 shares at a price of $13.00-$15.00 per share. Who are Eledon Pharmaceuticals' major shareholders? Eledon Pharmaceuticals' top institutional shareholders include Russell Investments Group Ltd. (0.16%), Daytona Street Capital LLC (0.11%), Farmers & Merchants Investments Inc. (0.09%) and Private Advisor Group LLC (0.02%). View institutional ownership trends. How do I buy shares of Eledon Pharmaceuticals? Shares of ELDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eledon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eledon Pharmaceuticals investors own include Cabaletta Bio (CABA), NVIDIA (NVDA), Oncolytics Biotech (ONCY), CohBar (CWBR), Hyperion DeFi (HYPD), Acumen Pharmaceuticals (ABOS) and Annexon (ANNX). Company Calendar Last Earnings8/13/2026Today11/12/2026Next Earnings (Estimated)11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 As of 2 days ago, ELDN's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ELDN CIK1404281 Webwww.eledon.com Phone(949) 238-8090FaxN/AEmployees33Year Founded2004Price Target and Rating Average Price Target for Eledon Pharmaceuticals$10.00 High Price Target$12.00 Low Price Target$8.00 Potential Upside/Downside+274.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.62 million Net MarginsN/A Pretax MarginN/A Return on Equity-149.63% Return on Assets-50.84% Debt Debt-to-Equity RatioN/A Current Ratio7.90 Quick Ratio7.90 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.35 per share Price / Book1.98Miscellaneous Outstanding Shares81,261,000Free Float73,460,000Market Cap$216.97 million OptionableOptionable Beta0.95 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:ELDN) was last updated on 11/11/2026 by MarketBeat.com Staff. From Our PartnersWatch This NowJensen Huang, the man who launched the AI boom, just called what Elon Musk is chasing "the final frontier of A...StocksToTrade | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredThis 10.3% war bond closed once. It's finally open again.Todd Phillips has spent 30 years studying safe-money income. His test for real retirement income: can it promi...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eledon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eledon Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELDN Stock Alerts